

# Contents

Welcome Message .....	iii
EULAR 2016 Abstracts Reviewers .....	iv

## Speakers Abstracts

### Speaker Presentations

#### Wednesday, 8 June 2016

SP0001–SP0002	WIN session 1 .....	2
SP0003–SP0005	Catastrophizing pain in RA .....	2
SP0006	Axial spondyloarthritis and psoriatic arthritis: emerging pathways .....	3
SP0007	HOT session 1 .....	3
SP0008–SP0011	Balancing benefits and risk of glucocorticoids; a challenge for implementation .....	3
SP0012–SP0013	What CVD outcomes to use in clinical rheumatological practice? .....	5
SP0014–SP0017	Different perspectives on pain in osteoarthritis .....	5
SP0018–SP0020	Epigenetics solving the OA puzzle .....	6
SP0021–SP0022	Muscle biology & inflammation .....	7
SP0023–SP0025	Lessons from the children (monogenic causes of autoimmunity) .....	7
SP0026–SP0027	ABC of statistics .....	8
SP0028–SP0031	Capillaroscopy I .....	8
SP0032–SP0033	Optimizing treatment and patient care through precision medicine: a threat or an opportunity for patients and patient organisations? .....	9
SP0034–SP0036	EULAR projects in Musculoskeletal Imaging .....	10
SP0037	Difficult osteoporosis .....	10
SP0038	Clinical relevance of immunogenicity and therapeutic drug monitoring .....	11
SP0039–SP0040	Hepatitis C and rheumatology: the impact of new therapies .....	11
SP0041–SP0043	Outcome measures in clinical practice in gout and CPPD. The use of the new EULAR guidelines ...	11
SP0044–SP0045	Hand osteoarthritis: state of the art and future perspectives .....	12
SP0046–SP0047	Chronobiology of the immune response .....	13
SP0048–SP0050	Nanomedicine in rheumatology .....	13
SP0051–SP0052	HOT session 2 .....	14
SP0053–SP0056	Beyond EMEUNET: development of a European-wide network of young clinicians from different specialties focusing on inflammatory diseases .....	14
SP0057	Data visualisation: tables and graphs for publication and presentation I .....	15
SP0058–SP0060	Ultrasound basic I .....	16
SP0061	Patient organisations in action .....	16
SP0062–SP0063	Hot topics in paediatric rheumatology .....	16

#### Thursday, 9 June 2016

SP0064–SP0065	Plasma cells as key players and therapeutic target in rheumatic diseases .....	17
SP0066–SP0068	Global year against joint pain .....	17
SP0069–SP0070	HOT session 4 .....	18
SP0071–SP0073	Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease .....	18
SP0074	WIN session 3 .....	19
SP0075–SP0076	Advancements in the imaging of PsA .....	19
SP0077–SP0079	When and how to treat Raynaud's phenomenon and related complications .....	20
SP0080–SP0081	Role of new imaging techniques as RMD outcomes .....	20
SP0082–SP0085	"Fewer words - more action" - tailored care for men with rheumatic diseases? .....	20
SP0086	Recent advances in our understanding of macrophage biology .....	21

SP0087–SP0088	Lubricants: potential as osteoarthritis treatment? .....	21
SP0089	Extraarticular complications of JIA .....	22
SP0090	The elephant in the room: how to avoid biases in research? .....	22
SP0091–SP0093	Digital applications for the benefit of the patient .....	23
SP0094–SP0095	EULAR projects in Clinical Affairs .....	23
SP0096–SP0097	Optimization of MTX in RA treatment .....	24
SP0098	Joint replacement in OA: friend or foe? .....	24
SP0099–SP0102	Physical activity assessment - what do we know, what do we do, how does it work? .....	25
SP0103–SP0104	How cell death shapes immunity and tolerance .....	26
SP0105–SP0107	“Smoke a joint to protect the joint”. Cannabidoids & neuropeptides in pain and inflammation .....	26
SP0108	EULAR - EMA session .....	27
SP0109–SP0110	Teaching clinical skills .....	27
SP0111–SP0113	Local procedures including aspirations, injections and biopsies I .....	27
SP0114–SP0117	MRI I .....	28
SP0118–SP0121	The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis .....	29
<b>Friday, 10 June 2016</b>		
SP0122	News from kinase inhibitors .....	29
SP0123–SP0125	Crystal arthritis .....	30
SP0126	HOT session 7 .....	30
SP0127	WIN session 6 .....	31
SP0128	Difficult to treat rheumatoid arthritis .....	31
SP0129	Biomarkers: powerful or powderpuff? .....	31
SP0130	HOT session 8 .....	31
SP0131–SP0132	The role of nuclear medicine in rheumatology .....	31
SP0133–SP0134	PROMs/PROs in rheumatological research - time for a critical appraisal? .....	32
SP0135–SP0137	Collaboration for success. User-centred design for improvement of health services .....	32
SP0138	ER stress & rheumatic disease .....	33
SP0139–SP0140	Role of imaging in childhood-onset rheumatic diseases .....	33
SP0141	Physician-patient relationship in the era of interactive media .....	34
SP0142	Capillaroscopy II .....	35
SP0143–SP0146	Ultrasound advanced I .....	35
SP0147–SP0148	It’s in your hands .....	36
SP0149	The EULAR School of Rheumatology - a new era of education .....	36
SP0150	Vaccination in rheumatic patients: a two-edged sword .....	37
SP0151–SP0153	Advances in large vessel vasculitis .....	37
SP0154	HOT session 9 .....	38
SP0155	When and how to diagnose and treat vitamin D deficiency? .....	38
SP0156	Data harmonization across (rheumatoid arthritis) clinical cohorts and registers .....	38
SP0157–SP0159	Telemedicine and e-health in community care .....	39
SP0160	Inflammasome as therapeutic target in inflammatory diseases .....	39
SP0161	What’s new: latest advances in treatment and management of systemic sclerosis and fibromyalgia ..	39
SP0162	EULAR projects in Investigative Rheumatology .....	40
<b>Saturday, 11 June 2016</b>		
SP0163	WIN session 8 .....	40
SP0164–SP0165	The elderly patient with osteoarthritis .....	40
SP0166–SP0168	SLE: what will it be and how will it be treated 5 years from now .....	40
SP0169	HOT session 10 .....	41
SP0170	“Time is joint”: early recognition and treatment of arthritis .....	41
SP0171–SP0173	Clinical outcomes for PMR/GCA .....	41
SP0174–SP0175	Getting active against rheumatoid arthritis fatigue .....	42
SP0176	Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis .....	43
SP0177	Cell-cell interaction in joint inflammation .....	43
SP0178–SP0179	Transition of care .....	43
SP0180–SP0181	New approaches to understanding and managing chronic musculoskeletal pain .....	43
SP0182	Seronegative inflammatory arthritis: diagnostic and management challenges .....	44

SP0183	HOT session 11 .....	44
SP0184–SP0186	Paget’s and other rare bone diseases .....	45
SP0187–SP0189	Analytical issues of complex databases .....	45
SP0190–SP0193	Intimate life and sexual relations in RA .....	46
SP0194–SP0195	Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis ...	47
SP0196	Adiposity as a driver of arthritis through inflammatory mechanisms .....	47
SP0197–SP0200	EULAR educational offer .....	47
SP0201–SP0203	There is more than drugs .....	48

## Scientific Abstracts

### Oral Presentations

#### Wednesday, 8 June 2016

OP0001–OP0002	Axial spondyloarthritis and psoriatic arthritis: emerging pathways .....	52
OP0003	Balancing benefits and risk of glucocorticoids; a challenge for implementation .....	53
OP0004–OP0005	What CVD outcomes to use in clinical rheumatological practice? .....	54
OP0006-HPR	Different perspectives on pain in osteoarthritis .....	55
OP0007–OP0008	Epigenetics solving the OA puzzle .....	55
OP0009–OP0010	Muscle biology & inflammation .....	56
OP0011–OP0012	Lessons from the children (monogenic causes of autoimmunity) .....	56
OP0013	ABC of statistics .....	57
OP0014-PARE	Optimizing treatment and patient care through precision medicine: a threat or an opportunity for patients and patient organisations? .....	58
OP0015–OP0016	Clinical relevance of immunogenicity and therapeutic drug monitoring .....	58
OP0017–OP0018	Outcome measures in clinical practice in gout and CPPD. The use of the new EULAR guidelines .....	59
OP0019-HPR	Hand osteoarthritis: state of the art and future perspectives .....	60
OP0020–OP0021-HPR	Chronobiology of the immune reponse .....	60
OP0022–OP0023	Nanomedicine in rheumatology .....	61
OP0024-PARE–OP0025-PARE	Patient organisations in action .....	61

#### Thursday, 9 June 2016

OP0026–OP0027	Plasma cells as key players and therapeutic target in rheumatic diseases .....	62
OP0028–OP0029	Global year against joint pain .....	63
OP0030–OP0038	Diagnosis and management of SSc .....	64
OP0039–LB0001	Advances in SLE therapeutics .....	68
OP0159–OP0166	New pathways to treatment .....	116
OP0053–LB0002	Vasculitis .....	74
OP0060-HPR–OP0067-HPR	Developing evidence-based non-pharmacological care .....	77
OP0068–OP0075	Cartilage, bone, synovium .....	80
OP0076–OP0083	SpA and PsA basic and translational research .....	83
OP0084–OP0091	SpA and PsA clinical .....	86
OP0092–OP0099	New horizons in osteoarthritis .....	89
OP0100–OP0107	Clinical osteoporosis: new insights .....	92
OP0175–OP0182	Prognosis and outcome in RA .....	122
OP0116-PARE–OP0117-PARE	Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease .....	99
OP0118–OP0125	New insights into imaging .....	100
OP0126–OP0127	Advancements in the imaging of PsA .....	103
OP0128–OP0129	When and how to treat Raynaud’s phenomenon and related complications .....	104
OP0130–OP0131	Role of new imaging techniques as RMD outcomes .....	105
OP0132-HPR	“Fewer words - more action” - tailored care for men with rheumatic diseases? .....	106
OP0133–OP0134	Recent advances in our understanding of macrophage biology .....	106
OP0135	Lubricants: potential as osteoarthritis treatment? .....	107
OP0136–OP0137	Extraarticular complications of JIA .....	107
OP0138	The elephant in the room: how to avoid biases in research? .....	108
OP0139-PARE–OP0140-PARE	Digital applications for the benefit of the patient .....	108

OP0141–OP0142	Optimization of MTX in RA treatment .....	109
OP0143–OP0144	Joint replacement in OA: friend or foe? .....	110
OP0145–OP0146	How to identify and follow patients with inflammatory back pain? .....	111
OP0147-HPR	Physical activity assessment - what do we know, what do we do, how does it work? .....	112
OP0148	How cell death shapes immunity and tolerance .....	112
OP0149–OP0150	“Smoke a joint to protect the joint”. Cannabidoids & neuropeptides in pain and inflammation .....	112
OP0151	Teaching clinical skills .....	113
OP0152-PARE–OP0153-PARE	What is done for people with rare diseases? Can we do more? .....	113
OP0154-HPR	The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis .....	114
<b>Friday, 10 June 2016</b>		
OP0155–OP0156	News from kinase inhibitors .....	114
OP0157–OP0158	Crystal arthritis .....	115
OP0045–OP0052	Scleroderma, myositis and related conditions .....	71
OP0167–OP0174	Epidemiology of RMDs .....	119
OP0108–OP0115	Expanding therapeutic options in spondyloarthritis .....	95
OP0183–OP0190	SLE, Sjögren’s and APS: clinical aspects (other than treatment) .....	126
OP0191-HPR–OP0198-HPR	Shared decision making .....	129
OP0199–OP0206	Novel insights into B and T cell immunity in rheumatic disease .....	132
OP0207–OP0214	An inflammatory update! .....	135
OP0215–OP0222	Advances in paediatric rheumatology .....	138
OP0223–OP0230	Developments in the treatment of RA .....	141
OP0231–OP0238	Emerging concepts in genomics & genetics .....	145
OP0239–OP0246	Novel clues solved in RA development .....	148
OP0247-PARE–OP0254-PARE	PARE abstract session .....	152
OP0255–OP0262	Cormobidities .....	154
OP0263–OP0264	Biomarkers: powerful or powderpuff? .....	158
OP0265–OP0266	The role of nuclear medicine in rheumatology .....	158
OP0267-HPR–OP0268	PROMs/PROs in rheumatological research - time for a critical appraisal? .....	159
OP0269-HPR	Collaboration for success. User-centred design for improvement of health services .....	160
OP0270–OP0271	ER stress & rheumatic disease .....	160
OP0272–OP0273	Joint EULAR - EFIS session: Do stromal cells house and cure immune cells? .....	161
OP0274–OP0275	Role of imaging in childhood-onset rheumatic diseases .....	162
OP0276–OP0277-PARE	Physician-patient relationship in the era of interactive media .....	162
OP0278-PARE	It’s in your hands .....	163
OP0279	The EULAR School of Rheumatology - a new era of education .....	163
OP0280–OP0281	Advances in large vessel vasculitis .....	164
OP0282–OP0283	When and how to diagnose and treat vitamin D deficiency? .....	165
OP0284–OP0285	Data harmonization across (rheumatoid arthritis) clinical cohorts and registers .....	165
OP0286-HPR	Telemedicine and e-health in community care .....	166
OP0287	Inflammasome as therapeutic target in inflammatory diseases .....	166
OP0289–OP0290	Potential targets in inflammatory fibrotic conditions in SSc .....	167
<b>Saturday, 11 June 2016</b>		
OP0291	SLE: What will it be and how will it be treated 5 years from now .....	168
OP0292–OP0293	Clinical outcomes for PMR/GCA .....	168
OP0294-HPR–OP0295-HPR	Getting active against rheumatoid arthritis fatigue .....	169
OP0296–OP0297	Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis. ....	170
OP0298–OP0299	Cell-cell interaction in joint inflammation .....	170
OP0300–OP0301	Transition of care .....	171
OP0302-PARE–OP0303-PARE	New approaches to understanding and managing chronic musculoskeletal pain .....	172
OP0304–OP0305	Picking knowledge from other medical disciplines for SSc .....	172
OP0306	Paget’s and other rare bone diseases .....	173
OP0307	Analytical issues of complex databases .....	174
OP0308-HPR	Intimate life and sexual relations in RA .....	174

OP0309–OP0310	Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis ...	174
OP0311–OP0312	Adiposity as a driver of arthritis through inflammatory mechanisms .....	175
OP0313-PARE–OP0314-PARE	There is more than drugs .....	176

## Late Breaking Abstracts

### Thursday, 9 June 2016

LB0001	Advances in SLE therapeutics .....	70
LB0002	Vasculitis .....	77

## Poster Presentations

### Thursday, 9 June 2016

#### Guided Poster Tours

T1: THU0001–THU0010	Immunity in rheumatic diseases .....	178
T2: THU0016–THU0023	Cartilage, bone, synovium .....	183
T3: THU0029–THU0036	Prognosis and outcome in RA .....	187
T4: THU0073–THU0082	Comorbidities update 2016, part 1 .....	205
T5: THU0165–THU0173	RA treatments - non-biological, small molecules .....	243
T6: THU0213–THU0222	Arthritis in childhood .....	264
T7: THU0240–THU0251	Walk through new pathways, biomarkers and potential treatments in SLE and Sjögren's ..	275
T8: THU0363–THU0372	SpA and PsA basic an translational research .....	318
T9: THU0374–THU0383	Axial SpA - clinical aspects .....	322
T10: THU0418–THU0427	Psoriatic arthritis .....	340
T11: THU0456–THU0465	How to treat osteoporosis in patients with elevated disease .....	357
T12: THU0490–THU0499	Crystal and metabolic bone diseases; bone diseases other than osteoporosis .....	369
T13: THU0541–THU0550	Clinical aspects of fibromyalgia .....	388
T14: THU0593–THU0602	Outcome measures of RMDs .....	406
T15: PARE0001–PARE0008	PARE Poster tour I .....	1320

#### Posters

THU0001–THU0015	Adaptive immunity (T cells and B cells) in rheumatic diseases .....	178
THU0016–THU0028	Cartilage, synovium and osteoimmunology .....	183
THU0029–THU0072	Rheumatoid arthritis - prognosis, predictors and outcome .....	187
THU0073–THU0119	Rheumatoid arthritis - comorbidity and clinical aspects .....	205
THU0120–THU0164	Rheumatoid arthritis - anti-TNF therapy .....	223
THU0165–THU0211	Rheumatoid arthritis - non-biologic treatment and small molecules .....	243
THU0212	Basic science in paediatric rheumatology .....	264
THU0213–THU0239	Paediatric rheumatology .....	264
THU0240–THU0281	SLE, Sjögren's and APS - etiology, pathogenesis and animal models .....	275
THU0282–THU0314	SLE, Sjögren's and APS - treatment .....	289
THU0315–THU0362	SLE, Sjögren's and APS - clinical aspects (other than treatment) .....	301
THU0363–THU0373	Spondyloarthritis - etiology, pathogenesis and animal models .....	318
THU0374–THU0417	Spondyloarthritis - clinical aspects (other than treatment) .....	322
THU0418–THU0455	Psoriatic arthritis .....	340
THU0456–THU0489	Osteoporosis .....	357
THU0490–THU0540	Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis ..	369
THU0541–THU0560	Fibromyalgia .....	388
THU0561–THU0591	Other orphan diseases .....	394
THU0593–THU0638	Epidemiology, health services and outcome research .....	406

### Friday, 10 June 2016

#### Guided Poster Tours

F1: FRI0001–FRI0007	Time for some fun with molecules .....	426
F2: FRI0042–FRI0051	Biology of RA I .....	441
F3: FRI0106–FRI0114	Comorbidities update 2016, part 2 .....	466
F4: FRI0154–FRI0163	RA treatment: predictors, tapering and biosimilars .....	484
F5: FRI0198–FRI0207	Safety and efficacy of non-TNF $\alpha$ blockers in the treatment of RA - I .....	502

F6: FRI0238–FRI0246	From research to biomarkers and targeting SSc .....	520
F7: FRI0248–FRI0257	Scleroderma, myositis and related syndromes I .....	523
F8: FRI0305–FRI0314	SLE and APS - clinical aspects .....	545
F9: FRI0354–FRI0362	Vasculitis I .....	563
F10: FRI0394–FRI0404	SPA - clinical .....	577
F11: FRI0513–FRI0522	Imaging in RMD - adding value .....	624
F12: FRI0550–FRI0560	Epidemiology of RMDs .....	639
F13: FRI0599–FRI0608	Education .....	659
F14: FRI0643-HPR–FRI0652-HPR	Focus on rehabilitation .....	1286
F15: PARE0009–PARE0017	PARE Poster tour II .....	1322

### Posters

FRI0001–FRI0041	Cytokines and inflammatory mediators .....	426
FRI0042–FRI0061	Rheumatoid arthritis - etiology, pathogenesis and animal models .....	441
FRI0062–FRI0105	Rheumatoid arthritis - prognosis, predictors and outcome .....	448
FRI0106–FRI0153	Rheumatoid arthritis - comorbidity and clinical aspects .....	466
FRI0154–FRI0197	Rheumatoid arthritis - anti-TNF therapy .....	484
FRI0198–FRI0237	Rheumatoid arthritis - other biologic treatment .....	502
FRI0238–FRI0239	Scleroderma, myositis and related syndromes .....	520
FRI0240–FRI0247	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models .....	520
FRI0248–FRI0304	Scleroderma, myositis and related syndromes .....	523
FRI0305–FRI0353	SLE, Sjögren's and APS - clinical aspects (other than treatment) .....	545
FRI0354–FRI0393	Vasculitis .....	563
FRI0394–FRI0438	Spondyloarthritis - clinical aspects (other than treatment) .....	577
FRI0439–FRI0478	Psoriatic arthritis .....	594
FRI0479–FRI0512	Other orphan diseases .....	611
FRI0513–FRI0549	Diagnostics and imaging procedures .....	624
FRI0550–FRI0598	Epidemiology, health services and outcome research .....	639
FRI0599–FRI0609	Education .....	659

### Saturday, 11 June 2016

#### Guided Poster Tours

S1: SAT0001–SAT0010	Genetic basis and genomics of disease .....	664
S2: SAT0021–SAT0030	Innate immune cells coming to play .....	671
S3: SAT0042–SAT0051	Biology of RA II .....	678
S4: SAT0144–SAT0153	Safety and efficacy of non-TNF $\alpha$ blockers in the treatment of RA - II .....	716
S5: SAT0184–SAT0194	Basic research in systemic sclerosis .....	735
S6: SAT0195–SAT0204	Scleroderma, myositis and related syndromes II .....	738
S7: SAT0253–SAT0262	Juvenile-onset connective tissue diseases .....	760
S8: SAT0281–SAT0290	SLE and Sjögren's: clinical aspects .....	769
S9: SAT0330–SAT0338	Vasculitis II .....	786
S10: SAT0371–SAT0380	Optimising treatment of axial SpA .....	801
S11: SAT0424–SAT0433	New insights in osteoarthritis .....	824
S12: SAT0481–SAT0490	Infection related rheumatic diseases .....	844
S13: SAT0502–SAT0511	New approaches to back pain - soft tissue problems .....	851
S14: SAT0528–SAT0537	Imaging RMD: what else? .....	860
S15: SAT0637-HPR–SAT0644-HPR	Getting around rheumatic disease .....	1294

### Posters

SAT0001–SAT0020	Genomics, genetic basis of disease and HLA/T cell recognition .....	664
SAT0021–SAT0030	Innate immunity in rheumatic diseases .....	671
SAT0031–SAT0051	Rheumatoid arthritis - etiology, pathogenesis and animal models .....	675
SAT0052–SAT0095	Rheumatoid arthritis - prognosis, predictors and outcome .....	682
SAT0096–SAT0143	Rheumatoid arthritis - comorbidity and clinical aspects .....	700
SAT0144–SAT0183	Rheumatoid arthritis - other biologic treatment .....	716
SAT0184–SAT0194	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models .....	735
SAT0195–SAT0252	Scleroderma, myositis and related syndromes .....	738

SAT0253–SAT0280	Paediatric rheumatology	760
SAT0281–SAT0329	SLE, Sjögren's and APS - clinical aspects (other than treatment)	769
SAT0330–SAT0370	Vasculitis	786
SAT0371–SAT0423	Spondyloarthritis - treatment	801
SAT0424–SAT0480	Osteoarthritis	824
SAT0481–SAT0501	Infection-related rheumatic diseases	844
SAT0502–SAT0527	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	851
SAT0528–SAT0566	Diagnostics and imaging procedures	860
SAT0567–SAT0614	Epidemiology, health services and outcome research	874
SAT0615–SAT0626	Rehabilitation	892

### Abstracts Accepted for Publication

AB0001–AB0012	Genomics, genetic basis of disease and HLA/T cell recognition	897
AB0013–AB0026	Adaptive immunity (T cells and B cells) in rheumatic diseases	901
AB0027–AB0028	Innate immunity in rheumatic diseases	906
AB0029–AB0058	Cytokines and inflammatory mediators	906
AB0059–AB0078	Cartilage, synovium and osteoimmunology	917
AB0079–AB0114	Rheumatoid arthritis - etiology, pathogenesis and animal models	923
AB0115–AB0124	Spondyloarthritis - etiology, pathogenesis and animal models	936
AB0125–AB0160	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	939
AB0161–AB0164	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	951
AB0165–AB0166	Basic science in paediatric rheumatology	952
AB0167–AB0258	Rheumatoid arthritis - prognosis, predictors and outcome	953
AB0259–AB0296	Rheumatoid arthritis - comorbidity and clinical aspects	988
AB0297–AB0337	Rheumatoid arthritis - anti-TNF therapy	1001
AB0338–AB0381	Rheumatoid arthritis - other biologic treatment	1017
AB0382–AB0405	Rheumatoid arthritis - non-biologic treatment and small molecules	1035
AB0406–AB0426	SLE, Sjögren's and APS - treatment	1045
AB0427–AB0525	SLE, Sjögren's and APS - clinical aspects (other than treatment)	1053
AB0526–AB0581	Vasculitis	1084
AB0582–AB0653	Scleroderma, myositis and related syndromes	1103
AB0654–AB0664	Spondyloarthritis - treatment	1128
AB0665–AB0721	Spondyloarthritis - clinical aspects (other than treatment)	1132
AB0722–AB0749	Psoriatic arthritis	1151
AB0750–AB0767	Osteoarthritis	1161
AB0768–AB0798	Osteoporosis	1167
AB0799–AB0834	Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis	1177
AB0835–AB0836	Infection-related rheumatic diseases	1188
AB0837–AB0842	Fibromyalgia	1189
AB0843–AB0854	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	1191
AB0855–AB0891	Paediatric rheumatology	1194
AB0892–AB0929	Other orphan diseases	1207
AB0930–AB0982	Diagnostics and imaging procedures	1219
AB0983–AB1056	Epidemiology, health services and outcome research	1237
AB1057–AB1062	Rehabilitation	1263
AB1063–AB1073	Education	1265

## Health Professionals in Rheumatology Abstracts

### Oral Presentations

#### Wednesday, 8 June 2016

OP0006-HPR	Different perspectives on pain in osteoarthritis	55
OP0019-HPR	Hand osteoarthritis: State of the art and future perspectives	60
OP0021-HPR	Chronobiology of the immune response	60

**Thursday, 9 June 2016**

OP0060-HPR–OP0067-HPR	Developing evidence-based non-pharmacological care .....	77
OP0132-HPR	“Fewer words - more action” - tailored care for men with rheumatic diseases? .....	106
OP0147-HPR	Physical activity assessment - what do we know, what do we do, how does it work? .....	112
OP0154-HPR	The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis .....	114

**Friday, 10 June 2016**

OP0191-HPR–OP0198-HPR	Shared decision making .....	129
OP0267-HPR	PROMs/PROs in rheumatological research - time for a critical appraisal? .....	159
OP0269-HPR	Collaboration for success. User-centred design for improvement of health services .....	160
OP0286-HPR	Telemedicine and e-health in community care .....	166

**Saturday, 9 June 2016**

OP0294-HPR–OP0295-HPR	Getting active against rheumatoid arthritis fatigue .....	169
OP0308-HPR	Intimate life and sexual relations in RA .....	174

**Poster Presentations****Thursday, 9 June 2016****Posters**

THU0639-HPR–THU0651-HPR	Miscellaneous forms of clinical care .....	1270
-------------------------	--	------

**Friday, 10 June 2016****Guided Poster Tours**

F14: FRI0643-HPR–FRI0652-HPR	Focus on rehabilitation .....	1286
------------------------------	-------------------------------	------

**Posters**

FRI0610-HPR–FRI0652-HPR	Physiotherapy & miscellaneous forms of clinical care .....	1275
-------------------------	--	------

**Saturday, 11 June 2016****Guided Poster Tours**

S15: SAT0637-HPR–SAT0644-HPR	Getting around rheumatic disease .....	1294
------------------------------	--	------

**Posters**

SAT0627-HPR–SAT0636-HPR	Nursing .....	1290
SAT0637-HPR	Miscellaneous forms of clinical care .....	1294
SAT0638-HPR	Psychology/Social sciences .....	1294
SAT0639-HPR	Nursing .....	1294
SAT0640-HPR	Miscellaneous forms of clinical care .....	1295
SAT0641-HPR	Nursing .....	1295
SAT0642-HPR	Psychology/Social sciences .....	1295
SAT0643-HPR	Miscellaneous forms of clinical care .....	1296
SAT0644-HPR	Nursing .....	1296
SAT0645-HPR–SAT0648-HPR	Psychology/Social sciences .....	1297
SAT0649-HPR	Occupational therapy .....	1298

**Abstracts Accepted for Publication**

AB1074-HPR–AB1085-HPR	Nursing .....	1299
AB1086-HPR–AB1092-HPR	Psychology / Social sciences .....	1303
AB1093-HPR–AB1110-HPR	Physiotherapy .....	1305
AB1111-HPR–AB1113-HPR	Occupational therapy .....	1311
AB1114-HPR–AB1130-HPR	Miscellaneous forms of clinical care .....	1312



## People with Arthritis and Rheumatism in Europe Abstracts

### Oral Presentations

#### Wednesday, 8 June 2016

OP0014-PARE	Optimizing treatment and patient care through precision medicine: A threat or an opportunity for patients and patient organisations? .....	58
OP0024-PARE–OP0025-PARE	Patient organisations in action .....	61

#### Thursday, 9 June 2016

OP0116-PARE–OP0117-PARE	Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease .....	99
OP0139-PARE–OP0140-PARE	Digital applications for the benefit of the patient .....	108
OP0152-PARE–OP0153-PARE	What is done for people with rare diseases? Can we do more? .....	113

#### Friday, 10 June 2016

OP0247-PARE–OP0254-PARE	PARE abstract session .....	152
OP0277-PARE	Physician-patient relationship in the era of interactive media .....	163
OP0278-PARE	It's in your hands .....	163

#### Saturday, 11 June 2016

OP0302-PARE–OP0303-PARE	New approaches to understanding and managing chronic musculoskeletal pain .....	172
OP0313-PARE–OP0314-PARE	There is more than drugs .....	176

### Poster Presentations

#### Thursday, 9 June 2016

##### Guided Poster Tours

T15: PARE0001–PARE0008	PARE Poster tour I .....	1320
------------------------	--------------------------	------

#### Friday, 10 June 2016

##### Guided Poster Tours

F15: PARE0009–PARE0017	PARE Poster tour II .....	1322
------------------------	---------------------------	------

#### Thursday, 9 June to Saturday, 11 June 2016

##### Posters

PARE0001–PARE0004	Patient information and education .....	1320
PARE0005–PARE0006	Building patient led organisations .....	1321
PARE0007	Best practice campaigning .....	1322
PARE0008	Building patient led organisations .....	1322
PARE0009	Best practice campaigning .....	1322
PARE0010–PARE0011	Patient information and education .....	1323
PARE0012	Best practice campaigning .....	1324
PARE0013	Patient information and education .....	1324
PARE0014	Best practice campaigning .....	1324
PARE0015	Innovations in arthritis health care .....	1325
PARE0016	Arthritis research .....	1325
PARE0017	Patient information and education .....	1325

<b>Author Index</b> .....	1327
---------------------------	------